Compare NMAI & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMAI | CGC |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.6M | 389.2M |
| IPO Year | N/A | 2023 |
| Metric | NMAI | CGC |
|---|---|---|
| Price | $13.81 | $0.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.95 |
| AVG Volume (30 Days) | 123.5K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-06-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 84.17 |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | N/A | $21.39 |
| Revenue Next Year | N/A | $8.33 |
| P/E Ratio | $21.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.99 | $0.81 |
| 52 Week High | $15.06 | $2.38 |
| Indicator | NMAI | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 44.21 | 27.61 |
| Support Level | $13.49 | N/A |
| Resistance Level | $13.90 | $0.98 |
| Average True Range (ATR) | 0.34 | 0.03 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 38.66 | 9.71 |
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.